540729 Stock Overview
Operates as a preclinical contract research organization in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Vanta Bioscience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹41.07 |
| 52 Week High | ₹101.64 |
| 52 Week Low | ₹37.01 |
| Beta | 0.81 |
| 11 Month Change | 0.15% |
| 3 Month Change | -16.18% |
| 1 Year Change | -23.75% |
| 33 Year Change | -60.89% |
| 5 Year Change | -70.87% |
| Change since IPO | -18.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540729 | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -5.2% | 1.2% | 0.3% |
| 1Y | -23.7% | 48.2% | 27.3% |
Return vs Industry: 540729 underperformed the Indian Life Sciences industry which returned 47.9% over the past year.
Return vs Market: 540729 underperformed the Indian Market which returned 27.2% over the past year.
Price Volatility
| 540729 volatility | |
|---|---|
| 540729 Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 540729's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 540729's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 48 | Dopesh Mulakala | www.vantabio.com |
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. It offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. The company also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies.
Vanta Bioscience Limited Fundamentals Summary
| 540729 fundamental statistics | |
|---|---|
| Market cap | ₹259.23m |
| Earnings (TTM) | -₹38.48m |
| Revenue (TTM) | ₹45.88m |
5.7x
P/S Ratio-6.7x
P/E RatioIs 540729 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540729 income statement (TTM) | |
|---|---|
| Revenue | ₹45.88m |
| Cost of Revenue | -₹13.07m |
| Gross Profit | ₹58.95m |
| Other Expenses | ₹97.43m |
| Earnings | -₹38.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.10 |
| Gross Margin | 128.50% |
| Net Profit Margin | -83.89% |
| Debt/Equity Ratio | 704.5% |
How did 540729 perform over the long term?
See historical performance and comparison